ISHL12 Program at a Glance

Saturday (22.10.2022)

Sunday (23.10.2022)

Monday (24.10.2022)

Großer Saal

07:30–09:00
Interactive Case Discussion

T. Illidge
J. Zijlstra

Case presentation: Greyzone Lymphoma
- L. Pinczés
Case presentation: Anti-PD1 Failure
- G. Collins
Case presentation: COVID19 immunity in lymphoma
- S. Mellinghoff
Case presentation: Primary progressive HL
- A. Jacob

Großer Saal

07:30–09:00
Advanced Stages

O. Casasnovas
J. Radford

Why I recommend BV-AVD
- R. Advani
Why I recommend PET-guided ABVD
- A. Fosså
Why I recommend PET-adapted escalated BEACOPP
- P. Borchmann
Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective
- M. Dreyling
- J. Richardson
- S. Wells
WS Report: Learning through International Collaboration
- P. Borchmann
- A. Moskowitz
FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
- W. Plattel
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
- P. Borchmann

07:30

08:45–10:15
Seminars and Workshops (parallel sessions)

Seminar: Living beyond Lymphoma
- L. Specht
- F. van Leeuwen
Workshop: The HL Microenvironment
- S. Rodig
- A. Rosenwald
Workshop: PET beyond Deauville
- S. Barrington
- M. Hutchings
- C. Kobe
Workshop: Innovation for Older Patients
- P. Bröckelmann
- A. Fosså
Joint EHA-ISHL Symposium
- P. Borchmann
- M. Dreyling

09:00

Coffee Break

Großer Saal

09:15–10:15
Emerging Cellular Therapies – a Role in HL?

S. Ansell
P. Borchmann

Clinical experience with Cellular Therapy in cH
- B. Savoldo
Design and manufacturing of CD30 CARs for cHL
- C. Quintarelli
Emerging indications for cellular therapy
- P. Borchmann

Großer Saal

09:15–10:15
Special Situations in HL

R. Hoppe
M. Kersten

HL in Pregnancy
- D. Dierickx
HIV-positive HL
- O. Baiocchi
alloSCT in the era of anti-PD1
- A. Sureda

09:15

10:15

Coffee Break

10:30–12:00
Seminars and Workshops (parallel sessions)

Seminar: Radiotherapy: Identifying the Beneficiaries
- C. Baues
- J. Yahalom
Workshop: Bringing Liquid Biopsy to Patients
- S. Borchmann
- D. Rossi
Seminar: Learning from Pediatric HL
- J. Friedberg
- C. Mauz-Körholz
Workshop: NLPHL
- M. Binkley
- D. Eichenauer
- S. Hartmann

Großer Saal

10:30–12:00
Living beyond Lymphoma

J. Radford
F. van Leeuwen

Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors
- K. Linton
GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study
- K. Behringer
WS Report: Living beyond Lymphoma
- L. Specht
- F. van Leeuwen
Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
- S. Neppelenbroek
Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
- J. Entrop
Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
- M. Dinan

Großer Saal

10:30–12:00
Genomics, Biology and Microenvironment

W. Klapper
R. Küppers

Biological Classification of HL by Liquid Biopsy
- S. Borchmann
Single Cell Transcriptomics of HL
- C. Steidl
WS Report: Bringing Liquid Biopsy to Patients
- S. Borchmann
- D. Rossi
Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
- K. Karihtala
High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
- A. Diepstra
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
- J. Paczkowska

10:30

12:00

Coffee Break

Großer Saal

12:15–13:45
Opening paths to the next chapters of lymphoma treatmen

by Beigene

In memoriam of Saul Rosenberg
- R. Advani
Welcome and Introduction to the topic
- P. Borchmann
Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma
- P. Bröckelmann
The challenge of the older patient in lymphoma therapy
- G. Collins
New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies
- P. Zinzani

Großer Saal

12:15–13:45
Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

by Takeda

G. Collins
A. Herrera
P. Zinzani

Welcome and introduction
- G. Collins
Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1
- G. Collins
Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)
- G. Collins
- A. Herrera
- P. Zinzani
Audience Q&A
Summary and close
- G. Collins

12:15

Großer Saal

12:30–13:30
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

by MSD

P. Borchmann

Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?
- P. Borchmann
The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma
- B. von Tresckow
Strategies to enhance checkpoint inhibition
- P. Bröckelmann

13:45

Coffee Break

Großer Saal

14:00–15:30
Early Stages

M. André
H. Eich

Standard treatment of early-stage HL
- J. Radford
Individual risk assessment of RT in HL
- R. Hoppe
WS Report: NLPHL
- M. Binkley
- D. Eichenauer
- S. Hartmann
Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
- D. Eichenauer
Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
- A. Gallamini
Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
- R. Shakir

Großer Saal

14:00–15:30
Older and Frail Patients

R. Cordoba Mascuñano
A. Evens

Managing an Older Lymphoma Patient
- R. Cordoba Mascuñano
Treatment Strategies in Older HL Patients
- A. Evens
Workshop Report: Innovation for Older patients
- P. Bröckelmann
- A. Fosså
AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
- N. Övergaard
The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
- J. Upshaw
Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
- I. Buvat

Großer Saal

14:00–15:30
Relapsed / Refractory HL

R. Advani
C. Moskowitz

1ˢᵗ Relapse of HL
- C. Moskowitz
Novel developments in R/R HL
- G. Collins
WS Report: PET beyond Deauville
- S. Barrington
- M. Hutchings
- C. Kobe
Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
- A. Sureda
High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
- A. Moskowitz
Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
- C. Diefenbach

14:00

15:30

Coffee Break

Großer Saal

15:30–16:00
Closing Remarks

Conference Highlights
- R. Advani

Großer Saal

16:00–17:30
CAR T cell therapy in B Cell NHL: Status quo and future perspectives

by Bristol-Myers Squibb

P. Borchmann
P. Cramer

Status quo of CAR T cell therapy for r/r DLBCL
- P. Borchmann
New perspective for the treatment of r/r CLL
- P. Cramer
CAR T – Lessons Learned
- C. Scheid

Großer Saal

16:00–17:30
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

by Takeda

A. Sureda

Welcome and introduction
- A. Sureda
Navigating Complex Treatment Decisions in R/R HL
- T. Vasilakopoulos
Challenging Case Study #1
- M. Hutchings
Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL
- A. Sureda
Challenging Case Study #2
- M. Hutchings
Audience Q&A

Foyer (First Floor)

16:00–16:30
Farewell

16:00

16:30

Coffee Break

Großer Saal

18:00–19:00
Opening and Award Ceremony

Welcoming Address
- A. Engert
Award Ceremony
- P. Borchmann
- S. Borchmann
- P. Bröckelmann
- D. Eichenauer
Introduction to the Keynote Lecturer
- V. Diehl
Keynote Lecture
- U. Şahin

Großer Saal

18:00–19:30
Immunotherapy

P. Armand
P. Zinzani

New findings and new challenges since last ISHL
- S. Ansell
Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
- R. Lynch
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- J. Timmerman
Vision Corner Stimulus Talk: The future of translational science in HL
- C. Steidl
Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment
- G. Collins
Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure
- P. Bröckelmann
Vision Corner: Discussion
- P. Bröckelmann
- G. Collins
- C. Steidl

18:00

19:00

Foyer (Ground Floor)

19:00–20:30
Poster Session

Kleiner Saal

19:00
Welcome Reception

20:30

07:30–09:00 Interactive Case Discussion

Case presentation: Greyzone Lymphoma

Case presentation: Anti-PD1 Failure

Case presentation: COVID19 immunity in lymphoma

Case presentation: Primary progressive HL

07:30–09:00 Advanced Stages

Why I recommend BV-AVD

Why I recommend PET-guided ABVD

Why I recommend PET-adapted escalated BEACOPP

Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

WS Report: Learning through International Collaboration

FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

08:45–10:15 Seminars and Workshops (parallel sessions)

Seminar: Living beyond Lymphoma

Workshop: The HL Microenvironment

Workshop: PET beyond Deauville

Workshop: Innovation for Older Patients

Joint EHA-ISHL Symposium

09:15–10:15 Emerging Cellular Therapies – a Role in HL?

Clinical experience with Cellular Therapy in cH

Design and manufacturing of CD30 CARs for cHL

Emerging indications for cellular therapy

09:15–10:15 Special Situations in HL

HL in Pregnancy

HIV-positive HL

alloSCT in the era of anti-PD1

10:30–12:00 Seminars and Workshops (parallel sessions)

Seminar: Radiotherapy: Identifying the Beneficiaries

Workshop: Bringing Liquid Biopsy to Patients

Seminar: Learning from Pediatric HL

Workshop: NLPHL

10:30–12:00 Living beyond Lymphoma

Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors

GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study

WS Report: Living beyond Lymphoma

Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

10:30–12:00 Genomics, Biology and Microenvironment

Biological Classification of HL by Liquid Biopsy

Single Cell Transcriptomics of HL

WS Report: Bringing Liquid Biopsy to Patients

Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

12:15–13:45 Opening paths to the next chapters of lymphoma treatmen

In memoriam of Saul Rosenberg

Welcome and Introduction to the topic

Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

The challenge of the older patient in lymphoma therapy

New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

12:15–13:45 Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

Welcome and introduction

Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1

Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)

Audience Q&A

Summary and close

12:30–13:30 Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

Strategies to enhance checkpoint inhibition

14:00–15:30 Early Stages

Standard treatment of early-stage HL

Individual risk assessment of RT in HL

WS Report: NLPHL

Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

14:00–15:30 Older and Frail Patients

Managing an Older Lymphoma Patient

Treatment Strategies in Older HL Patients

Workshop Report: Innovation for Older patients

AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

14:00–15:30 Relapsed / Refractory HL

1ˢᵗ Relapse of HL

Novel developments in R/R HL

WS Report: PET beyond Deauville

07:30–09:00
Interactive Case Discussion

07:30–09:00
Advanced Stages

08:45–10:15
Seminars and Workshops (parallel sessions)

09:15–10:15
Emerging Cellular Therapies – a Role in HL?

09:15–10:15
Special Situations in HL

10:30–12:00
Seminars and Workshops (parallel sessions)

10:30–12:00
Living beyond Lymphoma

10:30–12:00
Genomics, Biology and Microenvironment

12:15–13:45
Opening paths to the next chapters of lymphoma treatmen

12:15–13:45
Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

12:30–13:30
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

14:00–15:30
Early Stages

14:00–15:30
Older and Frail Patients

14:00–15:30
Relapsed / Refractory HL

15:30–16:00
Closing Remarks

16:00–17:30
CAR T cell therapy in B Cell NHL: Status quo and future perspectives

16:00–17:30
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

16:00–16:30
Farewell

18:00–19:00
Opening and Award Ceremony

18:00–19:30
Immunotherapy

19:00–20:30
Poster Session

19:00
Welcome Reception